Compare XPON & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPON | PMCB |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 4.0M |
| IPO Year | 2022 | 2001 |
| Metric | XPON | PMCB |
|---|---|---|
| Price | $2.50 | $0.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.8K | ★ 99.3K |
| Earning Date | 11-16-2026 | 12-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,651,870.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 71.59 | N/A |
| 52 Week Low | $0.26 | $0.30 |
| 52 Week High | $11.79 | $1.51 |
| Indicator | XPON | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 29.06 | 50.38 |
| Support Level | $0.51 | $0.32 |
| Resistance Level | $3.82 | $0.40 |
| Average True Range (ATR) | 0.34 | 0.04 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 14.21 | 58.20 |
Expion Energy Inc is engaged in premium lithium iron phosphate (LiFePO4) batteries and accessories for recreational vehicles, marine applications, Light EV and industrial applications. The company's lithium-ion batteries feature half the weight of standard lead-acid batteries while delivering three times the power and ten times the number of charging cycles. The company's batteries also feature construction and reliability compared to other lithium-ion batteries on the market due to their superior design and quality materials.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.